← back to search

Adrienne G. Waks

Harvard University · US
Area of research
Cancer Research · Oncology
Research interest
Research interests include Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, and Cancer Treatment and Pharmacology.
h-index
22
citations
8,546
works
214
NIH funding
primary concept
Medicine
email

Recent publications

Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot study
Breast Cancer Research and Treatment 2025cited by 3position: middledoi
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)
JCO Oncology Practice 2024cited by 13position: firstdoi
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
The Lancet Oncology 2023cited by 161position: middledoi
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
npj Breast Cancer 2022cited by 40position: firstdoi
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Cancer Discovery 2021cited by 236position: middledoi
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
Cancer Discovery 2020cited by 427position: middledoi
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Clinical Cancer Research 2020cited by 184position: middledoi
Breast Cancer Treatment
JAMA 2019cited by 4,802position: firstdoi
Breast Cancer Treatment
JAMA 2019cited by 237position: firstdoi
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
Nature Genetics 2018cited by 237position: middledoi
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Nature Communications 2017cited by 1,080position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Eric P. Winer · Yale University6 papers (2018–2022)Aviv Regev · Moscow Institute of Thermal Technology2 papers (2018–2020)Philip D. Poorvu · Harvard University2 papers (2022–2025)Laura M. Spring · Harvard University2 papers (2021–2022)Seth A. Wander · Harvard University2 papers (2018–2020)Otto Metzger · Harvard University2 papers (2021–2022)Ian E. Krop · Cancer Institute (WIA)2 papers (2021–2022)Ann H. Partridge · Harvard University2 papers (2022–2025) · 2 papers (2018–2020)Nancy U. Lin · San Francisco Art Institute2 papers (2018–2020)Samuel S. Freeman · Kettering University2 papers (2018–2020)Nikhil Wagle · Gene Therapy Laboratory2 papers (2018–2020)Orit Rozenblatt–Rosen · Broad Institute2 papers (2018–2020)Michael S. Cuoco · Broad Institute2 papers (2018–2020)Tari A. King · Harvard University2 papers (2021–2022)Ofir Cohen · Broad Institute2 papers (2018–2020)Franziska Michor · Harvard University1 papers (2021–2021)Tianyu Li · North China University of Science and Technology1 papers (2022–2022)Meredith Faggen · Harvard University1 papers (2022–2022)Vincent A. Miller · Universidad San Carlos1 papers (2020–2020)